Compounded GLP-1 and the FDA Shortage
503A/503B Pathway, Shortage Resolution, and the Crackdown
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Never FDA-approved; compounding now outside shortage-based enforcement discretion
Reference only. Not medical advice.
What can go wrong
Compounded GLP-1 products carried documented safety concerns: dosing errors (especially with patient self-measurement from vials), variable potency and purity, use of unapproved salt forms in some products, and absence of the manufacturer quality systems behind approved drugs. The FDA and manufacturers warned that compounded knockoffs may be dangerous. With the legal pathway closed, ongoing compounded supply increasingly falls outside enforcement discretion.
This is something to take to a clinician. The Atlas can tell you what is known about compounded glp-1 and the fda shortage in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
When branded semaglutide and tirzepatide were on the FDA drug shortage list, compounding pharmacies were permitted to prepare copies under sections 503A (state-licensed pharmacies) and 503B (outsourcing facilities). This fueled a large cash-pay compounded GLP-1 market. The FDA declared the semaglutide shortage resolved in February 2025 and set short enforcement-discretion windows before compounding had to stop, prompting litigation and a continuing regulatory crackdown.
A regulatory window that opened with shortage and closed with resolution.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Compounding pharmacies prepare drugs from bulk active pharmaceutical ingredient (API) or from approved drugs. Under 503A, state-licensed pharmacies compound for individual prescriptions; under 503B, outsourcing facilities compound at larger scale under cGMP-like standards. Federal law generally bars compounding copies of commercially available, FDA-approved drugs except when the drug is on the FDA shortage list. The shortage listing was therefore the legal foundation of the entire compounded GLP-1 market.
Why the window closed
Once the FDA determined supply could meet demand, it removed semaglutide (and earlier, tirzepatide) from the shortage list, eliminating the legal basis for compounding copies. The FDA granted brief enforcement-discretion windows (~60 days for 503A, ~90 days for 503B) to avoid abrupt patient disruption. The Outsourcing Facilities Association sought a preliminary injunction; a federal court denied it in April 2025. The agency has since moved toward permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, signaling no regulatory future for large-scale GLP-1 compounding.
What people get wrong
Often saidCompounded semaglutide is the same as Ozempic/Wegovy
ActuallyIt is not an FDA-approved product; potency, purity, and the specific molecule (including salt forms) could differ and were not subject to manufacturer quality control.
Often saidCompounding is still freely legal now that I am used to it
ActuallyThe shortage-based legal basis closed in 2025; large-scale compounding of these drugs is being phased out of permissible pathways.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
The compounded market thrived on price: cash compounded semaglutide was frequently advertised in the ~$199-$300/month range, far below branded list prices that approached or exceeded ~$1,000/month. The collapse of the compounding pathway, combined with manufacturer self-pay price cuts, reshaped the affordability landscape.
At a glance
- Sema shortage resolved
- Feb 21, 2025
- 503A enforcement window closed
- Apr 22, 2025 (~60 days)
- 503B enforcement window closed
- May 22, 2025 (~90 days)
- Approval status
- Compounded GLP-1s were never FDA-approved
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Compounded GLP-1 and the FDA Shortage. A short entry is not a safe entry.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.